Episode Details
Back to Episodes
Roche Shifts After Trial Fail, Cell Model Accelerates Cycle Simulations, Targeting PIEZO1 Halts Breast Cancer, China Approves Antibody Trial, and more...
Published 1 month ago
Description
(0:10): Roche's Breast Cancer Drug Trial Falls Short, Shifts Focus in Competitive SERD Market
(2:21): Revolutionary Cell Model Predicts Core Processes, Accelerates Cycle Simulation with Dual-GPU Strategy
(4:37): New Study Targets PIEZO1 Pathway to Halt Aggressive Breast Cancer Growth and Spread
(6:37): China Approves Trial for Breakthrough Antibody Targeting Atopic Dermatitis in Kelun-Biotech and Harbour BioMed Collaboration
(8:52): Gut Microbiome Revolutionizes Cancer Immunotherapy, Enhancing Outcomes and Reducing Toxicity
To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.
Image credit: www.investments.halifax.co.uk
(2:21): Revolutionary Cell Model Predicts Core Processes, Accelerates Cycle Simulation with Dual-GPU Strategy
(4:37): New Study Targets PIEZO1 Pathway to Halt Aggressive Breast Cancer Growth and Spread
(6:37): China Approves Trial for Breakthrough Antibody Targeting Atopic Dermatitis in Kelun-Biotech and Harbour BioMed Collaboration
(8:52): Gut Microbiome Revolutionizes Cancer Immunotherapy, Enhancing Outcomes and Reducing Toxicity
To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.
Image credit: www.investments.halifax.co.uk